Format

Send to

Choose Destination
Nat Rev Cancer. 2018 Feb;18(2):128-134. doi: 10.1038/nrc.2017.118. Epub 2018 Jan 12.

EMT in cancer.

Author information

1
Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, FAU University Erlangen-Nürnberg, Glückstr. 6, 91054 Erlangen, Germany.
2
Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
3
Instituto de Neurociencias CSIC-UMH, Avda. Ramón y Cajal s/n, 03550 San Juan de Alicante, Spain.
4
Whitehead Institute for Biomedical Research, Ludwig Massachusetts Institute for Technology (MIT) Center for Molecular Oncology and MIT Department of Biology, Cambridge, Massachusetts 02142, USA.

Abstract

Similar to embryonic development, changes in cell phenotypes defined as an epithelial to mesenchymal transition (EMT) have been shown to play a role in the tumorigenic process. Although the first description of EMT in cancer was in cell cultures, evidence for its role in vivo is now widely reported but also actively debated. Moreover, current research has exemplified just how complex this phenomenon is in cancer, leaving many exciting, open questions for researchers to answer in the future. With these points in mind, we asked four scientists for their opinions on the role of EMT in cancer and the challenges faced by scientists working in this fast-moving field.

PMID:
29326430
DOI:
10.1038/nrc.2017.118
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center